Report of Foreign Issuer (6-k)
August 07 2018 - 12:03PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer
Pursuant to Rule 13A-16
or 15d-16 of
The
Securities Exchange Act of 1934
For
the month of August 2018
COMMISSION
FILE Number.
000-29338
CORREVIO
PHARMA CORP.
(Translation
of registrant’s name into English)
1441
Creekside Drive, 6th floor
Vancouver,
British Columbia, V6J 4S7, CANADA
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
DOCUMENTS INCLUDED AS PART OF THIS REPORT
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
| |
CORREVIO
PHARMA CORP. |
| |
(Registrant) |
| |
|
|
| Date: August 7, 2018 |
By: |
/s/
Justin Renz |
| |
|
Name: Justin Renz |
| |
|
Title: Chief Financial Officer |
Exhibit 99.1
Correvio To Report Second Quarter 2018
Financial Results On August 14, 2018
NASDAQ: CORV TSX: CORV
Conference Call Scheduled
for Tuesday,
August 14, 2018 at 4:30 p.m. Eastern (1:30 p.m. Pacific)
VANCOUVER, Aug. 7, 2018 /CNW/ - Correvio Pharma
Corp. (NASDAQ: CORV / TSX: CORV), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs,
today announced that it will report financial results for the second quarter ended June 30, 2018 on Tuesday, August 14, 2018. Correvio
will hold a conference call and webcast at 4:30 p.m. Eastern (1:30 p.m. Pacific) on that day to discuss the results.
To access the conference call, please dial
416-764-8688 or 888-390-0546 and use conference ID 12980324. The webcast can be accessed through the following link:
https://event.on24.com/wcc/r/1806440/C0B9D6FC0E2132792B5ECB68F02E7308
Webcast and telephone replays of the conference
call will be available approximately two hours after the completion of the call through August 28, 2018. Please dial
416-764-8677 or 888-390-0541 and enter code 980324 # to access the replay.
About Correvio Pharma Corp.
Correvio Pharma Corp. is a revenue-generating,
specialty pharmaceutical company focused on providing innovative, high-quality brands that meet the needs of acute care physicians
and patients. With a commercial presence and distribution network covering over 60 countries worldwide, Correvio develops, acquires
and commercializes brands for the in-hospital, acute care market segment. The Company's portfolio of approved and marketed brands
includes: Xydalba™ (dalbavancin hydrochloride), for the treatment of acute bacterial skin and skin structure infections
(ABSSSI); Zevtera®/Mabelio® (ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment
of community- and hospital-acquired pneumonia (CAP, HAP); Brinavess® (vernakalant IV) for the rapid conversion of
recent onset atrial fibrillation to sinus rhythm; Aggrastat® (tirofiban hydrochloride) for the reduction of thrombotic
cardiovascular events in patients with acute coronary syndrome, and Esmocard® and Esmocard Lyo® (esmolol
hydrochloride), a short-acting betablocker used to control rapid heart rate in a number of cardiovascular indications. Correvio's
pipeline of product candidates includes Trevyent®, a drug device combination that is designed to deliver treprostinil,
the world's leading treatment for pulmonary arterial hypertension. Correvio is traded on the NASDAQ Capital Market (CORV) and the
Toronto Stock Exchange (CORV). For more information, please visit our web site www.correvio.com.
Correvio® and the Correvio Logo
are the proprietary trademarks of Correvio Pharma Corp.
Aggrastat® and Brinavess® are trademarks owned by Correvio and its affiliates worldwide.
Xydalba™ is a trademark of Allergan Pharmaceuticals International Limited, and used under license. Zevtera®
and Mabelio® are trademarks owned by Basilea Pharmaceutica International Ltd., and used under license.
Esmocard® and Esmocard Lyo® are trademarks owned by Orpha-Devel Handels und Vertriebs GmbH, and used
under license.
Trevyent® is a trademark of SteadyMed Therapeutics, Inc. and used under license.
All other trademarks are the property of their respective owners.
View
original content:http://www.prnewswire.com/news-releases/correvio-to-report-second-quarter-2018-financial-results-on-august-14-2018-300691875.html
SOURCE Correvio Pharma Corp
View original content: http://www.newswire.ca/en/releases/archive/August2018/07/c3674.html
%CIK: 0001036141
For further information: Justin Renz, CFO, Correvio Pharma
Corp., 604.677.6905 ext. 128, 800.330.9928, jrenz@correvio.com; Argot Partners, Michelle Carroll/Claudia Styslinger, 212.600.1902,
michelle@argotpartners.com/claudia@argotpartners.com
CO: Correvio Pharma Corp
CNW 08:00e 07-AUG-18
This regulatory filing also includes additional resources:
ex991.pdf
Correvio Pharma (NASDAQ:CORV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Correvio Pharma (NASDAQ:CORV)
Historical Stock Chart
From Apr 2023 to Apr 2024
